COMT and Parkinson disease: Despite its clinical use and pharmacological properties, including the capacity to cross the blood–brain barrier (BBB) and thus inhibit central COMT, tolcapone is also associated with high hepatoxicity, limiting its use in more advanced cases of PD progression.